Loading
Syneos Health, Inc. Stock: price and insider trades · United States
Syneos Health, Inc.: what insiders have been doing
Syneos Health, Inc., founded in 1999, is a Healthcare & Pharma company based in Burlington, United States. Its directors and officers file their transactions with SEC (Form 4). The past year has been quiet: not a single insider filing for Syneos Health, Inc. The previous disclosure was published on 28 September 2023.
The full history, which starts in 2016, counts no purchases against 51 sales.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
174
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€1B
51 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$4.6B
Gross profitUS$347.6M7% margin
Net incomeUS$229.5M4.9% margin
Last declaration on 28 September 2023
Declarations174 total
3,493 shares@ US$43.00100.0% of flowClass A Common StockSEC:0001209191-23-050777:0
20,147 shares@ US$43.00100.0% of flowClass A Common StockSEC:0001209191-23-050774:0
14,368 shares@ US$43.0044.7% of flowClass A Common StockSEC:0001209191-23-050767:0
3,522 shares@ US$43.00100.0% of flowClass A Common StockSEC:0001209191-23-050771:0
14,906 shares@ US$43.0041.9% of flowClass A Common StockSEC:0001209191-23-050765:0
35,938 shares@ US$43.0053.2% of flowClass A Common StockSEC:0001209191-23-050764:0
4,973 shares@ US$43.00100.0% of flowClass A Common StockSEC:0001209191-23-050776:0
11,348 shares@ US$43.0089.9% of flowClass A Common StockSEC:0001209191-23-050768:0
9,915 shares@ US$43.00100.0% of flowClass A Common StockSEC:0001209191-23-050772:0
19,777 shares@ US$43.0096.8% of flowClass A Common StockSEC:0001209191-23-050775:0
3,042 shares@ US$43.0028.7% of flowClass A Common StockSEC:0001209191-23-050769:0
22,629 shares@ US$43.00100.0% of flowClass A Common StockSEC:0001209191-23-050770:0
51,433 shares0Class A Common StockSEC:0001209191-23-050766:0
7,370 shares0Class A Common StockSEC:0001209191-23-050773:0
3,615 shares0Class A Common StockSEC:0001209191-23-048201:0
236 shares@ US$42.292.1% of flowClass A Common StockSEC:0001209191-23-042606:0
51,433 shares0Class A Common StockSEC:0001209191-23-042608:0
220 shares@ US$41.811.6% of flowClass A Common StockSEC:0001209191-23-037966:0
4,863 shares0Class A Common StockSEC:0001209191-23-032934:0
4,863 shares0Class A Common StockSEC:0001209191-23-032928:0
4,863 shares0Class A Common StockSEC:0001209191-23-032930:0
4,863 shares0Class A Common StockSEC:0001209191-23-032938:0
4,863 shares0Class A Common StockSEC:0001209191-23-032942:0
4,863 shares0Class A Common StockSEC:0001209191-23-032940:0
4,863 shares0Class A Common StockSEC:0001209191-23-033057:0
25 of 174 declarations
About Syneos Health, Inc.
Syneos Health, Inc. is a global biopharmaceutical services company historically positioned as an integrated partner across the drug-development and commercialization continuum. The company was formed in 2017 through the merger of INC Research and inVentiv Health, combining clinical development capabilities with commercial services expertise. Its headquarters are in Morrisville, North Carolina, United States. During its public-market life, the stock traded on the NASDAQ under the ticker SYNH. The company was taken private in 2023 by a consortium of private investment firms, but its prior public listing remains relevant for understanding its SEC filing history and insider-transaction context. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1610950/000119312518005914/d517914dex991.htm?utm_source=openai))
Syneos Health’s core business is built around helping pharmaceutical and biotechnology sponsors bring therapies from research into market. On the development side, it provides clinical-trial execution, site management, regulatory support, and field-based operational services. On the commercialization side, it offers consulting, medical affairs, commercialization strategy, and commercial execution services. This “end-to-end” model is a key differentiator versus narrower CRO peers, particularly for customers running complex, multi-stage programs that require continuity from clinical proof-of-concept through launch planning and market activation. The value proposition is centered on reducing cycle times, improving efficiency, and aligning clinical evidence generation with downstream commercial outcomes. ([syneoshealth.com](https://www.syneoshealth.com/index.php/solutions?utm_source=openai))
Read moreShow less
From a competitive standpoint, Syneos Health operates in a crowded and highly competitive outsourced biopharma-services market. Its historical edge has been the combination of CRO capabilities and commercial solutions under one roof, which appeals to sponsors seeking a single strategic partner and greater coordination across the product lifecycle. That integrated model matters in an environment where drug developers are under pressure to control costs, accelerate enrollment and evidence generation, and deploy more digital and data-enabled workflows. Syneos has consistently marketed itself as a fully integrated biopharmaceutical solutions organization, emphasizing speed, transparency, and cross-functional expertise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1610950/000119312520296531/d34469dex991.htm?utm_source=openai))
Geographically, the business has had a broad international footprint, historically serving clients in more than 110 countries, while maintaining a strong operational base in the United States. Recent company communications underscore ongoing investment in artificial intelligence, data, and workflow automation. In May 2026, Syneos Health announced expanded strategic AI partnerships to enhance commercial precision performance and field-team execution. Prior communications in late 2024 and 2025 also highlighted AI-driven healthcare trends and the company’s broader emphasis on technology-enabled solutions across clinical and commercial activities. For investors, these developments suggest a continuing push toward higher-value, tech-enabled service delivery in a structurally important segment of the healthcare value chain. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1610950/000119312518005914/d517914dex991.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
